Breast Cancer Pathology Report Explained: Grade, Margins, Lymphovascular Invasion, Ki-67 and More

A breast cancer pathology report can look intimidating. You may see terms such as invasive carcinoma, Nottingham grade, tumor size, margins, lymph nodes, lymphovascular invasion, ER, PR, HER2 and Ki-67—sometimes all on the same page. It is easy to read the report and focus on one number or one word. But breast cancer treatment is rarely decided from one result alone. Doctors use these findings, along with imaging, clinical examination and staging, to understand the cancer and plan treatment. This guide supports the Breast Cancer Treatment in India pathway and the diagnosis explainer.

A pathology report is prepared after a pathologist examines a tissue sample. The sample may come from a core needle biopsy, surgical biopsy, lumpectomy or mastectomy. The pathologist examines the tissue under a microscope and may perform additional tests to identify the type and characteristics of the cancer. The final report can help establish the diagnosis, contribute to staging and guide treatment planning.

For breast cancer, the report can contain considerably more information than simply saying "cancer present." It may tell your treatment team the type of cancer, whether it is invasive, tumor size, tumor grade, whether lymph nodes contain cancer, whether lymphovascular invasion is present, whether the surgical margins are clear, ER, PR and HER2 status, Ki-67, and other pathological or molecular findings. Not every pathology report contains exactly the same sections.

A biopsy usually examines a small portion of the abnormal area. A surgical specimen may contain the entire tumor and surrounding tissue. Because a larger specimen provides more tissue to examine, the final surgical pathology report may contain information that was not available from the original biopsy — more accurate tumor size, margins, lymphovascular invasion, lymph-node involvement, the extent of invasive disease and associated DCIS. This is why your final pathology report after surgery may look considerably longer than your original biopsy report.

One of the first things to look for is whether the report describes the cancer as in situ or invasive. In situ disease remains within the structure where it originated. For example, ductal carcinoma in situ (DCIS) is confined to the milk ducts. Invasive breast cancer has grown beyond the original structure into surrounding breast tissue. The distinction matters because invasive breast cancer can have access to lymphatic and blood vessels and therefore has the potential to spread beyond the breast.

The pathology report may identify the type of breast cancer. Common types include invasive ductal carcinoma, invasive lobular carcinoma, DCIS and special histologic subtypes. Invasive ductal carcinoma is the most common invasive type. Invasive lobular carcinoma begins in the milk-producing lobules and has some different pathological characteristics. The histologic type is one piece of the overall picture. It is not usually enough on its own to determine treatment.

The pathology report may state the size of the invasive tumor, usually in millimetres or centimetres. For example, "Invasive carcinoma: 18 mm" means the measured invasive component is 18 millimetres. Tumor size contributes to the T category of breast cancer staging. It does not tell you the complete stage. Doctors also consider lymph nodes, distant spread and other factors.

Grade is not the same as stage. This is one of the most important distinctions to understand. Grade describes what the cancer cells look like under the microscope and how closely they resemble normal breast cells. Breast cancer commonly uses the Nottingham grading system. The pathologist evaluates tubule or gland formation, nuclear appearance and mitotic activity. Each receives a score, which is combined to produce the overall grade.

Grade 1 cells generally look more similar to normal breast cells and tend to have less aggressive microscopic features. Grade 2 is intermediate — more abnormalities than Grade 1 but fewer than Grade 3. Grade 3 cells look considerably different from normal breast cells and generally have features associated with faster growth. The grade can contribute to prognosis and treatment planning, but it should always be interpreted alongside the rest of the pathology and staging information.

Grade asks: "What do the cancer cells look like and how abnormal are they?" Stage asks: "How much cancer is there and where has it spread?" A Grade 3 cancer is not automatically Stage 3. Likewise, a lower-grade cancer can still be advanced if it has spread beyond the breast. See stages 0–4.

You may see something like "Nottingham score: 6/9." The score is calculated from the three microscopic features used for grading. The usual interpretation is 3–5 for Grade 1, 6–7 for Grade 2 and 8–9 for Grade 3. These ranges are based on the standard Nottingham grading approach. A score should not be interpreted separately from tumor type, stage and biomarkers.

Margins are the edges of the tissue removed during surgery. Imagine the surgeon removes the tumor together with a surrounding area of tissue. The pathologist examines the edges of that specimen to determine whether cancer cells extend all the way to the examined edge. The exact margin assessment and its clinical meaning depend on the type of cancer and the operation performed.

A negative margin generally means that cancer cells were not found at the examined surgical edge. You may also hear clear margin, clean margin or negative margin. These terms generally indicate that no cancer cells were identified at the relevant specimen edge.

A positive or involved margin means cancer cells are present at the edge of the removed tissue. This can mean that additional treatment or surgery may need to be considered. The next step depends on the specific pathology, operation and treatment plan. A positive margin should not be interpreted as proof that cancer has already spread throughout the body. It is a finding about the edge of the surgical specimen.

You may see "LVI: Present" or "Lymphovascular invasion: Not identified." Lymphovascular invasion means that cancer cells are seen within small lymphatic or blood vessels in or around the tumor. It can indicate a greater potential for cancer cells to travel outside the primary tumor. It does not automatically mean that the cancer has spread to distant organs. It is one pathological risk feature among several.

Lymph nodes are small structures that form part of the immune system. Breast cancer can spread to nearby lymph nodes, particularly those in the axilla, or underarm. A report that says "0/3 lymph nodes involved" generally means that three lymph nodes were examined and none contained cancer. "2/12 lymph nodes positive" means cancer was found in two of the 12 examined nodes. The number and location of involved nodes contribute to the N category of staging.

During some breast cancer surgeries, doctors remove one or more sentinel lymph nodes — the first nodes to which cancer cells are likely to travel from the breast. A negative sentinel-node result can provide important staging information. A positive result does not automatically mean distant metastatic disease. See lymphedema after lymph-node treatment.

ER stands for estrogen receptor. If breast cancer cells have estrogen receptors, the cancer is described as ER-positive. Estrogen can stimulate the growth of hormone receptor-positive breast cancer, so patients may be candidates for endocrine or hormone therapy. The report may provide both the receptor status and the percentage of cells showing staining.

PR stands for progesterone receptor. The report may state PR positive or negative, the percentage of cells positive and the intensity of staining. ER and PR are interpreted together with other features of the cancer because hormone-receptor status can influence systemic treatment. See ER, PR and HER2 treatment.

HER2 stands for human epidermal growth factor receptor 2. Some breast cancers have higher levels of HER2 or increased HER2 gene activity and may be eligible for HER2-targeted treatments. Testing can involve immunohistochemistry, commonly reported as 0, 1+, 2+ or 3+. A 2+ result may require additional testing, such as in-situ hybridisation. Interpret HER2 using the complete report rather than a single number.

Ki-67 is a marker of cell proliferation. It gives an indication of how many tumor cells are actively going through the cell cycle and dividing. You may see a result such as Ki-67: 15% or Ki-67: 40%. A higher percentage generally indicates greater proliferative activity. Ki-67 is one of the more frequently misunderstood parts of a breast cancer report.

Not by itself. Higher Ki-67 can be associated with faster-growing cancer, but there is no single universally reliable Ki-67 cutoff that works for every patient and every laboratory. ASCO has noted limitations in the standardisation and interpretation of Ki-67, particularly for intermediate values. A result such as 25% should not automatically be labelled "high risk" without considering ER, PR, HER2, grade, tumor size, lymph-node status, stage and other genomic or molecular tests.

Some pathology reports mention necrosis. Necrosis means that some tumor tissue has died. It can sometimes be described in association with particular tumor types or pathological patterns. Its significance depends on the overall pathology rather than simply whether the word "necrosis" appears.

This is generally a favorable pathological finding compared with the presence of lymphovascular invasion. It means the pathologist did not identify cancer cells within the lymphatic or blood vessels examined in the specimen. It does not guarantee that cancer has not spread elsewhere. Staging still requires consideration of lymph nodes, imaging and other clinical information.

DCIS stands for ductal carcinoma in situ. Some invasive breast cancers occur alongside an area of DCIS. If the report says no DCIS is identified, it means the pathologist did not find DCIS in the examined specimen. This does not change the diagnosis of invasive cancer if invasive cancer is already present.

If a report says "Invasive carcinoma: 15 mm," the 15 mm measurement refers to the invasive portion of the tumor. There may also be a larger area of associated DCIS. This distinction can matter when interpreting the pathology and staging.

These terms describe more than one tumor focus. Multifocal generally means multiple tumor areas within the same region or quadrant of the breast. Multicentric generally refers to tumors occurring in different areas or quadrants. The distinction can influence surgical planning, although treatment decisions depend on the complete clinical picture.

Unifocal means that one main tumor focus was identified. This is generally straightforward, but it is only one component of the pathology report.

Some pathology reports may mention perineural invasion. This means cancer cells are seen surrounding or involving a nerve. It is less commonly emphasised in routine breast cancer reports than tumor size, grade, lymph nodes, margins and receptor status. If it appears on your report, ask your oncologist or pathologist how it affects your specific case.

Biomarkers are measurable features of cancer cells that can provide information about the disease and potential treatment options. Important breast cancer biomarkers include ER, PR, HER2 and Ki-67. Depending on the clinical situation, additional molecular or genomic testing may also be considered. NCI notes that biomarker testing is an important part of evaluating breast cancer and can help guide treatment.

Some patients with certain types of early-stage breast cancer may undergo genomic testing. Examples include Oncotype DX, MammaPrint, Prosigna and EndoPredict. These tests examine the activity of multiple genes. They are not required for every patient. In selected situations, they can help doctors estimate recurrence risk or determine whether chemotherapy is likely to provide meaningful benefit.

Not by itself. A report might show ER positive, PR positive, HER2 negative, Grade 2 and a tumor of 18 mm. That is useful information. An oncologist still needs to consider age, menopausal status, lymph-node findings, stage, medical history, imaging and other factors. The pathology report is a major part of the decision-making process — not the entire decision.

This is particularly useful when seeking a second opinion. A cancer centre may request the original pathology report, pathology slides, paraffin-embedded tissue blocks, immunohistochemistry reports and molecular test reports. The American Cancer Society notes that pathology material can sometimes be sent to another centre for review. This is especially relevant for international patients who may later travel for treatment.

Yes. A second pathologist can review the original tissue when the diagnosis is unusual, the pathology is complicated, treatment recommendations are unclear, the patient is seeking a second opinion, or the original report does not match the clinical findings. A second review does not necessarily mean the first report was wrong. Pathology interpretation can be complex, particularly in unusual tumors or borderline findings. Teams in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad can review original slides before recommending a change in plan.

If you are travelling to India for breast cancer treatment, bring the complete diagnostic record rather than only the latest report. Carry the original biopsy report, surgical pathology, ER, PR, HER2 and Ki-67 reports, genomic testing if performed, slides or tissue blocks when available, mammography, ultrasound and MRI reports, CT or PET-CT reports, the actual imaging files, the operative report, chemotherapy records, radiation summary, current medicines and previous treatment response. See the international-patient guide.

Hospitals in Delhi NCR and Mumbai can coordinate pathology review with surgical oncology, medical oncology and radiation oncology before a treatment plan is confirmed.

For international patients, the pathology report is often one of the first documents an oncology team needs to review. GAF Healthcare can coordinate the collection of medical records and help patients connect with appropriate cancer specialists in India for evaluation. Depending on the diagnosis, this may involve surgical oncology, medical oncology, radiation oncology, breast imaging, pathology review and genetic or molecular testing.

No. Grade describes the microscopic appearance and behavior of the cancer cells. Stage describes how extensive the cancer is and whether it has spread. They are separate concepts.

No. A positive margin means cancer cells were found at the edge of the removed surgical tissue. It does not mean that cancer has spread to distant organs.

No. Lymphovascular invasion means cancer cells were seen in lymphatic or blood vessels within the tumor. Lymph-node metastasis means cancer cells were found in lymph nodes. They are different pathological findings.

Ki-67 provides information about cell proliferation, but it should not be interpreted alone. The reliability and clinical usefulness of intermediate Ki-67 values can be limited.

Hormone receptor-positive breast cancers may be treated with endocrine therapy when clinically appropriate. The specific medicine depends on menopausal status, stage and previous treatment.

HER2 2+ on immunohistochemistry is generally considered an equivocal result and may require additional testing to determine HER2 status.

No. Negative lymph nodes are an important finding, but they do not guarantee that recurrence or distant spread is impossible.

It can be useful in selected situations, particularly when the diagnosis is unusual, the treatment plan is unclear or you are seeking care at another cancer centre.

Yes. Patients can ask their original hospital or pathology laboratory about obtaining slides or tissue blocks for review.

There is no single section that is universally most important. Tumor type, size, grade, margins, lymph-node status, ER, PR, HER2 and other findings are interpreted together.

A breast cancer pathology report is much more than a diagnosis. Grade 3 does not automatically mean Stage 3. Lymphovascular invasion does not automatically mean metastatic cancer. A positive margin does not mean cancer has spread throughout the body. A high Ki-67 should not be interpreted on its own. Look at the entire picture. If you are travelling to India, keep the original reports, imaging, treatment records and — when available — slides or tissue blocks.

• Breast Cancer Treatment in India
• Diagnosis and biopsy
• ER, PR and HER2 · HER2-positive treatment
• Hormone therapy
• Stages 0–4
• Surgery · lumpectomy vs mastectomy
• DCIS · invasive lobular carcinoma
• Follow-up tests · recurrence
• Breast-conserving surgery doctors
• Mastectomy doctors
• Chemotherapy doctors · hormone-therapy doctors
• International patients